Drug Profile

TQB 3558

Alternative Names: TQB3558

Latest Information Update: 28 Jul 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chia Tai Tianqing Pharmaceutical Group
Class Antineoplastics
Mechanism of Action TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jul 2023 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in China (PO, Tablet)
22 Jun 2020 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, In adults, In the elderly) in China (PO) (NCT04408079)
01 Jun 2020 Chia Tai Tianqing Pharmaceutical plans a phase I trial for Solid tumours (Late-stage disease) in China (PO) (NCT04408079)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com